Experience on the long‐term use of canakinumab in mevalonate kinase deficiency: A case series

Abstract

We really appreciated the article "Long-term efficacy of canakinumab in hyperimmunoglobulin D syndrome" recently published by your Journal. 1 Indeed, although the treatment has been approved for hyperimmunoglobulin D syndrome (or mevalonate kinase deficiency -MKD), scarce data are available from real-world experiences. The "cluster" clinical trial for drug approval showed that the